Skip to main content

A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Efficacy and Safety of Sugammadex in High-Risk Ambulatory Surgeries

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Efficacy and Safety of Sugammadex in High-Risk Ambulatory Surgeries

Evaluating the Effectiveness of Bilateral ESPB in Addition to Standard Analgesia at Reducing Opioid Consumption

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Evaluating the Effectiveness of Bilateral ESPB in Addition to Standard Analgesia at Reducing Opioid Consumption

Pictographs for Preventing Wrong-Patient Errors in NICUs

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Pictographs for Preventing Wrong-Patient Errors in NICUs

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Labor Protocol Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Labor Protocol Study

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 219
  • Page 220
  • Page 221
  • Page 222
  • Page 223
  • Page 224
  • Page 225
  • Page 226
  • Page 227
  • …
  • Next page Next
  • Last page Last
Subscribe to